Subscribe for Updates
Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.
WASHINGTON, DC – (June 17, 2021) AAM and its Biosimilars Council welcome today’s decision by the U.S. Supreme Court in California v. Texas that ensures America’s patients and taxpayers can continue to benefit from biosimilar access and competition in the marketplace that is made possible by the Affordable Care Act’s inclusion of a biosimilar pathway.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.